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Edited by Sandro SonninoAbstract Ceramide-1-phosphate (C1P) is emerging as a new
addition to the family of bioactive sphingolipid metabolites. At
low concentrations, C1P enhanced survival of NIH 3T3 ﬁbro-
blasts and A549 lung cancer cells, while at high concentrations,
it reduced survival and induced apoptosis. Apoptosis correlated
with degradation of C1P to pro-apoptotic ceramide. To examine
the role of endogenous C1P, expression of ceramide kinase, the
enzyme that produces C1P, was downregulated, which reduced
cellular proliferation, progression into S phase and enhanced
apoptosis induced by serum starvation. Our results suggest that
ceramide kinase determines the balance between pro-apoptotic
ceramide and anti-apoptotic C1P to regulate cell fate, reminis-
cent of its function in plants.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Sphingolipid metabolites, including ceramide and sphingo-
sine-1-phosphate, are potent bioactive lipids that mediate
many important cellular functions. Ceramide typically inhibits
cell growth and promotes apoptosis [1]. In contrast, S1P pro-
motes cell growth and inhibits apoptosis [2]. Ceramide-1-phos-
phate (C1P) is another phosphorylated bioactive sphingolipid
whose importance has only recently begun to be appreciated.
Based on sequence homology to sphingosine kinase 1, we
cloned a related lipid kinase that catalyzes the phosphorylation
of ceramide kinase (CerK) [3]. This provided new molecular
tools to investigate the physiological functions of C1P, leadingAbbreviations: ACD5, accelerated cell death 5; BrdU, 5-bromo-20-de-
oxyuridine; C1P, ceramide-1-phosphate; CerK, ceramide kinase; cP-
LA2, cytosolic phospholipase A2; EGF, epidermal growth factor;
PARP, poly(ADP-ribose)polymerase; PCD, programmed cell death;
siRNA, small interfering RNA
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0014-5793/$32.00  2007 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2007.01.041to the discovery of a novel role for C1P as a proximal mediator
of arachidonate release [4] and an allosteric activator of group
IVA cytosolic phospholipase A2 (cPLA2a) [5], a critical event
in the production of arachidonate-derived eicosanoids. Inter-
estingly, CerK has been identiﬁed as the accelerated cell death
5 (ACD5) gene product in Arabidopsis thaliana [6]. Plants har-
boring an ACD5 mutation undergo programmed cell death
(PCD) accompanied by increased accumulation of ceramide
prior to death. Indeed, exogenous C2-ceramide induces plant
PCD, whereas its phosphorylated derivative partially blocks
it, supporting a role for CerK in modulating cell death in
plants [6]. Yet, whether CerK has a similar function in mam-
malian cells has not been investigated. Here we examined the
role of CerK and its product C1P in survival, proliferation
and apoptosis of ﬁbroblasts and lung adenocarcinoma cells.2. Materials and methods
2.1. Materials
Serum and media were from Bioﬂuids (Rockville, MD). [c-32P] ATP
(3000 Ci/mmol) was purchased from Perkin–Elmer (Wellesley, MA).
Epidermal growth factor (EGF) was from Life Technologies (Gai-
thersburg, MD). Control (small interfering RNA) siRNA and siRNAs
speciﬁc for CerK were from Dharmacon (Lafayette, CO). C1P derived
from bovine brain sphingomyelin was obtained from Sigma–Aldrich
(St. Louis, MO) and solubilized in ethanol/dodecane (49:1, v/v) [4].
Anti-CerK antibodies were obtained from Exalpha (Maynard, MA),
anti-poly(ADP-ribose)polymerase (PARP) from Biomol (Plymouth
Meeting, PA), anti-b-tubulin and anti-ERK2 from Santa Cruz Bio-
technology (Santa Cruz, CA), and anti-caspase-3, anti-phosphorylated
(pThr202/pTyr204) ERK1/2, and anti-phosphorylated (pSer473) Akt
antibodies were obtained from Cell Signaling Technology (Beverly,
MA). Secondary antibodies were from Jackson Immuno Research
(West Grove, PA). All other reagents were from Sigma–Aldrich.2.2. Cell culture and transfection
NIH 3T3 cells (ATCC, CRL-1658) were maintained in DMEM
supplemented with 10% calf serum. A549 human lung adenocarcinoma
cells (ATCC, CCL-185) were cultured in DMEM/RPMI (1:1) with 10%
fetal bovine serum. CerK was downregulated with speciﬁc siRNA
(5 0-UGCCUGCUCUGUGCCUGUA and 5 0-UACAGGCACAGAG-
CAGGCA) as described [4]. To rule out oﬀ-target eﬀects, where
indicated, experiments were repeated with another siRNA from a
SMART Pool (siCerKb) targeted at a diﬀerent CerK sequence (5
0-CC-
ACUGACAUCAUCGUUACUU and 5 0-GUAACGAUGAUGUC-
AGUGGUU). Cells were transfected with siRNA using Dharmafect 1
(Dharmacon) as recommended by the manufacturer.ation of European Biochemical Societies.
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Ceramide levels in cells treated with C1P were determined enzymat-
ically, essentially as described [7]. Brieﬂy, cell lipids were extracted and
ceramide mass levels determined by enzymatic conversion to [32P]C1P
with diacylglycerol kinase (EMD Biosciences, San Diego, CA), fol-
lowed by TLC analysis and quantitation. Ceramide levels were nor-
malized to total lipid phosphate [8]. HPLC tandem mass
spectrometry measurement of C-16:0 species of C1P, ceramide, and
sphingomyelin was performed exactly as described [9].
2.4. Western blotting
Cells were scraped and resuspended in PBS and an equal volume of
lysis buﬀer (0.5 M Tris (pH 6.8), 30% glycerol, 10% SDS, 1 mM 2-
mercaptoethanol and Sigma protease inhibitor cocktail) was added.
Equal amounts of protein were then resolved by SDS–PAGE, transb-
lotted to nitrocellulose, and immunopositive bands visualized by en-
hanced chemiluminescence (Pierce Chemical Co., Rockford, IL).
2.5. Cell proliferation assays
The 5-bromo-20-deoxyuridine (BrdU) Labeling and Detection Kit I
(Roche, Indianapolis, IN) was used to measure cell proliferation. Cells
were starved overnight, then treated without or with 0.5% and 2% ser-
um for 14 h. BrdU was then added for an additional 4 h, and cells were
ﬁxed, stained, and examined by ﬂuorescence microscopy. A minimum
of four ﬁelds each were scored from duplicate samples. In some exper-
iments, cell growth was measured by adding WST-1 reagent (Roche)
and incubating at 37 C for 1 h. Absorbance was measured at
450 nm with background subtraction at 630 nm. Cell cycle was ana-
lyzed by ﬂow cytometry as previously described [10].
2.6. Cell death assays
Cells were ﬁxed by addition of an equal volume of PBS containing
4% paraformaldehyde and 4% sucrose and stained with 10 lg/ml Hoe-
chst 33342. Condensed, fragmented nuclei indicative of apoptosis were
counted [10]. Apoptosis was also assessed by measuring the disappear-
ance of full length PARP and the appearance of caspase-3 cleavage
product by western blotting with speciﬁc antibodies [10].Fig. 1. Eﬀect of C1P on cell proliferation and apoptosis. A549 human lung
presence of vehicle (open bars) or the indicated concentrations of exogenou
WST-1 dye reduction assay. Duplicate cultures of A549 (C) and NIH 3T3 (D
and then ﬁxed and stained with Hoechst. Apoptosis was scored as the percenta
3T3 (F) cells were cultured for 18 h in the absence of serum to induce apoptos
of C1P (ﬁlled bars), and apoptosis was again determined using Hoechst. *P2.7. Quantitative real time PCR
Quantitative determination of mRNA levels was performed as de-
scribed [11]. TRIzol Reagent was used to isolate total RNA and cDNA
was then prepared with Superscript II reverse transcriptase (Invitro-
gen, Carlsbad, CA). Pre-mixed primer–probe sets were purchased from
Applied Biosystems (Foster City, CA) and cDNA ampliﬁed and quan-
tiﬁed on an ABI 7900HT.3. Results and discussion
3.1. Bimodal eﬀect of exogenous C1P on cell proliferation and
apoptosis
C1P has been reported to promote the growth and survival
of a variety of cell types [12–15]. However, more recently, oth-
ers have suggested that C1P is cytotoxic, particularly at high
concentrations [16]. Treatment of A549 human lung adenocar-
cinoma cells with low concentrations of natural, long-chain
C1P (0.5–1 lM) increased cell proliferation as measured by
WST-1 dye reduction (Fig. 1A). However, when these cells
were incubated with higher concentrations of C1P, cell growth
and viability were markedly reduced in a dose-dependent man-
ner (Fig. 1A). This bimodal eﬀect of C1P on proliferation was
not cell type speciﬁc as a similar eﬀect was also observed with
NIH 3T3 ﬁbroblasts (Fig. 1B). Moreover, treatment of both
A549 cells (Fig. 1C) and NIH 3T3 ﬁbroblasts (Fig. 1D) with
concentrations of C1P of 5 lM or greater markedly increased
the number of cells displaying fragmented, condensed nuclei
indicative of apoptosis. To examine whether low concentra-
tions of C1P could also protect these cells from apoptosis, as
suggested by previous reports [14,15] and the data in
Fig. 1A, B, cells were induced to undergo apoptosis. Low con-carcinoma cells (A) and NIH 3T3 ﬁbroblasts (B) were cultured in the
s C1P (ﬁlled bars) for 16 h. Cell proliferation was measured with the
) cells were treated with vehicle (open bars) or C1P (ﬁlled bars) for 18 h
ge of cells displaying fragmented, condensed nuclei. A549 (E) and NIH
is in the presence of vehicle (open bars) or the indicated concentrations
< 0.05, by two-tailed t-test.
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tion, protected both A549 (Fig. 1E) and NIH 3T3 cells
(Fig. 1F) from apoptosis induced by serum deprivation.
3.2. Exogenous C1P is metabolized to ceramide
Given that numerous studies have correlated increased cera-
mide levels with induction of apoptosis [1] and that several li-
pid phosphate phosphatases have been shown to
dephosphorylate C1P to ceramide [17,18], it was of interest
to determine whether induction of apoptosis by high concen-
trations of natural C1P was due to conversion to ceramide. In-
deed, treatment of NIH 3T3 ﬁbroblasts with C1P for 16 h at a
concentration of 5 lM, which markedly increased apoptosis
(Fig. 1D), increased cellular ceramide levels by more than two-
fold (Fig. 2A). Signiﬁcant increases in ceramide were detected
within 4 h and increased further thereafter (Fig. 2B). 5 lM
C1P also increased ceramide levels in A549 cells (Fig. 2C).
However, non-apoptotic concentrations of C1P did not lead
to increased ceramide levels. Moreover, 1 lM C1P caused a
slight decrease in ceramide levels in these cells, consistent with
the observation that C1P can inhibit acid sphingomyelinase, an
enzyme that generates ceramide [14].Fig. 2. Eﬀect of C1P treatment on ceramide levels. NIH 3T3 ﬁbroblasts (A,B
(open bar) for the indicated concentrations of C1P (ﬁlled bars) for 16 h (A,C)
bars) (B). Lipids were then extracted and ceramide levels determined. Data ar
*P < 0.05 by two-tailed t-test. P < 0.05 by one-tailed t-test, but not signiﬁca
Fig. 3. Downregulation of CerK reduces cell proliferation. (A) A549 cells w
was isolated and mRNA levels of Cerk and 18 S RNA were determined by qu
cultures at 48 h were immunoblotted with anti-CerK or anti-tubulin as a load
symbols) or siRNA targeted to CerK (open symbols). After 24 h, cells were cu
an additional 24, 48, and 72 h and cell proliferation determined with WST-
siRNA targeted to CerK (ﬁlled bars). After 24 h, cells were serum-starved for
14 h. BrdU was added for an additional 4 h, cells were ﬁxed, stained, and D
nascent DNA. Data are means ± S.D. By two-tailed t-test: *P < 0.05 for siC3.3. Role of CerK in proliferation and apoptosis of A549 cells
To examine the role of endogenous C1P in regulation of
growth and apoptosis, expression of CerK, the enzyme that
produces C1P, was downregulated by speciﬁc siRNA. In
agreement with previous results [4], transfection of A549 cells
with siRNA targeted to CerK strongly reduced expression of
CerK mRNA by more than 60% (Fig. 3A). siCerK also mark-
edly reduced the 62 kDa protein band detected with anti-CerK
antibody that corresponded to the predicted MW of CerK
(Fig. 3A). Downregulation of CerK reduced cellular prolifera-
tion within 48 h when compared to cells transfected with con-
trol siRNA (Fig. 3B). Although as expected, addition of serum
greatly enhanced proliferation of A549 cells, CerK knockdown
even reduced their growth when cultured in the presence of ser-
um (Fig. 3B). Moreover, siCerK decreased entry of cells into
the S phase of the cell cycle, as determined by incorporation
of BrdU into nascent DNA (Fig. 3C).
Because CerK has been implicated in PCD in plants [6] and its
product, C1P, blocks apoptosis in a variety of mammalian cells
[14,15], it was of interest to determine whether CerK has a sim-
ilar function in mammalian cells. Downregulation of CerKwith
siRNA markedly enhanced apoptosis, noticeable within 48 h) and A549 human lung carcinoma cells (C) were treated with vehicle
or with vehicle for 6 h (open bar) or 5 lM C1P for 2, 4, and 6 h (ﬁlled
e expressed as pmol ceramide/nmol phospholipid and are means ± S.D.
nt by the two-tailed t-test.
ere transfected with control siRNA or siRNA targeted to CerK. RNA
antitative real-time PCR. Equal amounts of cell lysates from duplicate
ing control. (B) A549 cells were transfected with control siRNA (ﬁlled
ltured in the absence (triangles) or presence of 10% serum (squares) for
1. (C) A549 cells were transfected with control siRNA (open bars) or
8 h and then stimulated with the indicated concentration of serum for
NA synthesis measured by quantitating incorporation of BrdU into
ontrol vs. siCerK; P < 0.05 for serum vs. no serum.
Fig. 4. Eﬀect of downregulation of CerK on apoptosis. (A) A549 cells were transfected with control siRNA (open bars) or siRNA targeted to CerK
(ﬁlled bars). Cells were then cultured for the indicated times, ﬁxed, and apoptosis assessed by Hoechst staining. *P < 0.001. (B) Equal amounts of cell
lysates from duplicate cultures were resolved by SDS–PAGE and immunoblotted with antibodies against cleaved caspase-3, cleaved PARP, or ERK2
as a loading control. (C) Lipids were prepared from parallel samples, and the levels of C-16:0 species of C1P, ceramide (Cer) and sphingomyelin (SM)
measured by HPLC tandem mass spectroscopy. Data were normalized to DNA content and expressed as fold increase compared to siControl. n = 3,
*P < 0.05. (D) A549 cells transfected with siControl or siCerK were cultured for 40 h, then starved for 8 h before treatment with 100 ng/ml EGF for
the indicated times. Equal amounts of cell lysates were separated by SDS–PAGE and immunoblotted with phospho-ERK1/2 and phospho-Akt
antibodies. Blots were stripped and reprobed with anti-ERK2 as a loading control.
Table 1
Downregulation of CerK inhibits cell cycle progression induced by
EGF
Treatment Stimulus G0/G1 S G2/M
siControl None 80.9 ± 1.7 15.4 ± 1.2 3.6 ± 0.5
EGF 74.1 ± 5.4 21.7 ± 2.9 6.0 ± 2.4
siCerK None 85.5 ± 2.5 9.7 ± 1.7 4.7 ± 0.9
EGF 84.3 ± 2.8 10.4 ± 1.4 5.2 ± 1.5
A549 cells were transfected with control siRNA or siRNA targeted to
CerK. After 24 h, cells were serum-starved for 8 h and then cultured in
the absence or presence of EGF (100 ng/ml) for 18 h. Cellular DNA
was stained with propidium iodide and cell cycle analysis was per-
formed by ﬂow cytometry. Data are means ± S.D. of percent cells in
each cell cycle phase.
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condensed fragmented nuclei (Fig. 4A). In contrast, siControl
had no signiﬁcant eﬀects on apoptosis. Moreover, apoptosis
due to knockdown of CerK was accompanied by activation of
caspase-3, as assessed by cleavage of procaspase-3 into the p19
active form and cleavage of the typical caspase-3 substrate
PARP (Fig. 4B), using a monoclonal anti-caspase-3 antibody
that recognizes the cleaved 19-kDa subunit of active caspase-
3, but not full length procaspase-3, and an anti-PARP antibody
that detects mainly the 89-kDa cleaved form.
To ensure that the observed eﬀects were speciﬁc to reduction
of CerK expression, the eﬀects of a second siRNA targeted to a
diﬀerent CerK sequence (siCerKb) were examined. Transfec-
tion with siCerKb also markedly reduced expression of CerK,
as determined by real-time PCR (Supplement Fig. 1A) and
also signiﬁcantly increased apoptosis in A549 cells (Supple-
ment Fig. 1B), indicating a lack of oﬀ-target eﬀects of siCerK.
Knockdown of CerK led to a decrease in the levels of the
major species of C1P containing a palmitoyl (C16:0) N-acyl
chain, with a concomitant increase of its substrate, C16:0 cer-
amide, as well as an alternative ceramide product, C16:0 sphin-
gomyelin (Fig. 4C). The changes in sphingolipid metabolite
levels are consistent with the induction of apoptosis induced
by CerK knockdown.
EGF is a well-established growth factor for cancer cells.
Therefore, we next examined the eﬀect of downregulating
CerK on EGF-induced proliferation of A549 lung cancer cells.Cell cycle analysis revealed that EGF increased the fraction of
cells in the S phase of the cell cycle with a concomitant de-
crease in G0/G1 (Table 1). Importantly, reduction of CerK re-
duced the progression of the cells into S and G2/M phases of
the cell cycle, even in the presence of EGF, with a correspond-
ing increase in cells arresting in G0/G1 (Table 1).
Previous studies have shown that exogenous C1P can acti-
vate pro-growth signaling kinases such as ERK1/2 [19] and
Akt [15]. Because knockdown of CerK blocked EGF-induced
proliferation, we next asked whether CerK was required for
EGF-induced activation of ERK1/2 and Akt. EGF induced
rapid phosphorylation of both ERK1/2 and Akt in A549 cells
P. Mitra et al. / FEBS Letters 581 (2007) 735–740 739(Fig. 4D). Of note, downregulation of CerK strongly reduced
the ability of EGF to induce phosphorylation of both Akt and
ERK1/2, consistent with its role in EGF-mediated prolifera-
tion (Table 1).4. Conclusions
Earlier studies suggested that short-chain and natural C1P
are potent mitogens [12,13] and inhibit apoptosis [14]. In con-
trast, short-chain C1P has been shown to induce apoptosis in
neuroblastoma cells [20]. More recently, it was reported that
treatment of diverse cell types with high concentrations of
short-chain as well as natural C1P resulted in irreversible cyto-
toxic eﬀects and thus questioned whether C1P acts as a genuine
mitogenic agent [16]. The results described herein potentially
resolve this apparent controversial issue. We observed a bipha-
sic eﬀect of natural C1P, with low concentrations promoting
viability and survival but high concentrations reducing growth
and enhancing apoptosis. Moreover, we have shown that high
concentrations of exogenous C1P are converted to pro-apopto-
tic ceramide. Additionally, some of the discrepancies might be
due to diﬀerences in vehicles used for delivery of C1P to cells.
Previous studies dispersed C1P in methanol/dodecane [14],
while more recent studies employed ethanol/dodecane [4,21].
Indeed, a recent report has shown that diﬀerent delivery meth-
ods of the same concentration of C1P diﬀerentially reduce cell
proliferation and induce cell death [16]. To circumvent prob-
lems associated with exogenous addition of C1P, we employed
a molecular approach, using siRNA targeting CerK to deter-
mine the role of C1P in mammalian cells. Consistent with plant
CerK mutants (ACD5), downregulation of CerK in mamma-
lian cells reduced growth and promoted apoptosis. Although
how C1P promotes growth and survival is not yet known, there
are several likely mechanisms. First, C1P has been shown to in-
hibit acid sphingomyelinase, an enzyme that produces ceramide
[14]. More directly, CerK can reduce ceramide by converting it
to C1P, similar to its function in plants [6]. Consistent with this
idea, we observed that knockdown of CerK led to increased
ceramide. Third, C1P translocates and activates cPLA2a, which
produces arachidonate, the precursor for prostanoids [4], and
both PGE2 [22] and PGI2 [23] have been shown to reduce apop-
tosis. Fourth, C1P can activate pro-growth signaling kinases
such as ERK1/2 [19] and Akt [15]. Indeed, our results suggest
that CerK is permissive for activation of ERK1/2 and Akt by
EGF. Finally, C1P can induce the synthesis of sphingosine-1-
phosphate [24], an important pro-growth and anti-apoptotic
sphingolipid metabolite [25].
Collectively, our data adds a new dimension to the under-
standing of the metabolic interrelationship of pro-apoptotic
ceramide and anti-apoptotic C1P, and suggest that CerK is a
critical enzyme that inﬂuences their intracellular balance to
regulate cell growth and survival, reminiscent of its function
in A. thaliana, where it modulates PCD [6].
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